AbbVie Inc. operates as a global pharmaceutical enterprise, concentrating on the discovery, development, production, and commercialization of medicinal products across the world. Its extensive product portfolio addresses various therapeutic areas. For autoimmune and inflammatory conditions, the company provides HUMIRA, an injectable treatment for autoimmune and intestinal Behçet's diseases; SKYRIZI, aimed at adults with moderate to severe plaque psoriasis; and RINVOQ, a JAK inhibitor prescribed for moderate to severe active rheumatoid arthritis in adult patients. In oncology, AbbVie offers IMBRUVICA for adult patients diagnosed with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Additionally, it markets VENCLEXTA, a BCL-2 inhibitor utilized to treat adults suffering from CLL or SLL. For infectious diseases, MAVYRET is available for individuals with chronic HCV genotype 1-6 infection. Other significant offerings include CREON, a pancreatic enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella is indicated for irritable bowel syndrome with constipation and chronic idiopathic constipation. Lupron serves multiple purposes, providing palliative care for advanced prostate cancer, treating endometriosis and central precocious puberty, and alleviating anemia caused by uterine fibroids. The company also offers therapeutic applications of Botox. Furthermore, ORILISSA is a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women experiencing moderate to severe endometriosis pain. For Parkinson's disease, Duopa and Duodopa, a levodopa-carbidopa intestinal gel, are available. AbbVie's eye care segment features Lumigan/Ganfort, a bimatoprost ophthalmic solution designed to lower elevated intraocular pressure (IOP) in cases of open angle glaucoma (OAG) or ocular hypertension. Alphagan/Combigan, an alpha-adrenergic receptor agonist, also contributes to IOP reduction in OAG. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other ophthalmic products. For neurological conditions, Ubrelvy is prescribed for adults suffering from migraine, with or without aura. The company also engages in research collaborations, notably with Dragonfly Therapeutics, Inc. Established in 2012, AbbVie Inc. maintains its principal corporate offices in North Chicago, Illinois.
